摘要:
Objective To investigate the effect of DC-CIK cellular immune therapy in the treatment of patients with lung cancer and relevant indicators.Methods From January 2014 to January 2016 in department of respiratory,Shaanxi province Shaanxi Baoji People's Hospital,80 lung cancer patients were included as the research object.They were randomly divided into observation group and control group;the control group were treated with cisplatin combined with gemcitabine,the observation group also added with DCCIK;evaluate the curative effect of patients;3 months before and after treatment,patients' functional status was assessed,and the blood samples were collected from peripheral blood T cell subsets and serum levels of IFN-γ,IL-4,TNF-alpha,TGF-beta were analyzed,and calculate the ratio of Th1/Th2;at the end of 18 months follow-up,adverse reactions were evaluated.Results After treatment,the total efficiency of the observation group and disease control rate were significantly higher than those in control group (47.50% vs.32.50%,x2 =4.688,P =0.030;95.00% vs.77.50%,x2 =12.912,P =0.000);after treatment,the observation group's KPS scores were significantly higher than those in the control group (t =12.422,P =0.000);the observation group's CD3 +,CD4 +/CD8 + and NK were significantly higher than those in the control group (t =5.107,P =0.000;t =4.24.1,P =0.000,t =8.959,P =0.000);observation group's blood IFN-γ,IL-4,TNF-alpha level,Th1/Th2 were significantly higher than the control group (t =24.736,P =0.000;t =15.556,P =0.000;t =12.293,P =0.000;t =7.757,P =0.000),TGF beta levels significantly lower than the control group (t =10.824,P =0.000);the observation group's nausea and vomiting,the function of liver and kidney damage,thrombocytopenia incidence was significantly lower than the control group (x2 =15.603,P =0.000;x2 =15.603,P =0.000;x2 =5.128,P =0.024);the survival curve of patients in the observation group were better than that of the control group,and the difference was statistically significant (P < 0.05).Conclusion DC-CIK cell immunotherapy can effectively improve the clinical efficacy,reduce the incidence of adverse reactions,and effectively regulate the levels of immune cells and cytokines in patients with lung cancer.%目的 分析DC-CIK细胞免疫疗法治疗非小细胞肺癌患者的疗效及对相关指标的影响.方法 选取2014年1月-2016年1月陕西省宝鸡市人民医院呼吸内科收治的非小细胞肺癌患者80例作为研究对象,随机信封法分为观察组及对照组各40例.对照组采用顺铂联合吉西他滨治疗,观察组在对照组治疗基础上加用DC-CIK治疗.对患者近期疗效进行评估,治疗前及治疗结束3个月时对患者功能状态进行评估,并采集静脉血检测外周血T细胞亚群及血清中IFN-γ、IL-4、TNF-α、TGF-β水平,计算Th1/Th2比值,随访18个月并评估患者不良反应.结果 治疗后,观察组患者总有效率及疾病控制率均显著高于对照组(47.50% vs.32.50%,95.00% vs.77.50%,x2=4.688、12.912,P<0.05);治疗后2组KPS评分均升高,且观察组显著高于对照组(t=12.422,P=0.000);观察组CD3+、CD4+、CD4+/CD8+及NK水平显著高于对照组(t=5.107、4.241、8.959、2.847,P均=0.000),CD8+、Treg降低(t=5.969、2.293,P<0.05);观察组血中IFN-γ、IL-4、TNF-α、Th1/Th2水平显著高于对照组(t=24.736、15.556、12.293、7.757,P均=0.000),TGF-β水平显著低于对照组(t=10.824,P=0.000);观察组恶心呕吐、肝肾功能损伤、血小板减少发生率显著低于对照组(x2 =15.603、15.603、5.128,P<0.05);观察组患者生存曲线明显优于对照组,且差异有统计学意义(P <0.05).结论 采用DC-CIK细胞免疫疗法对非小细胞肺癌患者进行治疗可有效提高临床疗效,降低患者不良反应发生率,并有效调节患者血中免疫细胞及细胞因子水平.